MTX, disease progressed as leukemic invasion of left optic nerve. High dose chemotherapy followed by ASCT was performed. **Conclusion:** Diagnosis of IVL is challenging due to late onset macular edema. Related with high relapse rates with-high mortality, high-dose chemotherapy is the recommended management type currently.

https://doi.org/10.1016/j.htct.2022.09.1243

PP09

## THE RELATIONSHIP BETWEEN FERRITIN LEVEL AND THROMBOSIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Buğra Sağlam [1], Murat Albayrak [2], Abdulkerim Yıldız [3], Pınar Tıplıoğlu [4], Mesut Tığlıoğlu [4], Merih Reis Aras [2], Fatma Yılmaz [2], Hacer Berna Afacan Öztürk [2]

[1] *sanlıurfa Mehmet Akif Inan Training and Researh Hospitala*
[2] *University of Health Sciences Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Department of Hematology*
[3] *Gaziantep Dr. Ersin Arslan Training Researh Hospital, deartment of Hematology*
[4] *Hitit university Erol Olçok Training and Research Hospital, Department of Hematology, Çorum*

**Objective:** Cancer is a well-known condition associated with its treatment and follow-up and increases the risk of thrombosis. As with solid tumors, the risk of venous thromboembolism (VTE) is quite high in lymphomas, especially high-grade B-cell lymphomas. Diffuse large B-cell lymphoma (DLBCL) patients are the most important part of this group. The aim of our study is to determine the effect of ferritin level at the time of diagnosis on thrombosis in DLBCL patients. **Methodology:** In this retrospective study, 133 patients who applied to SBU Dışkapı Yıldırım Beyazıt Training and Research Hospital Hematology clinic and were diagnosed with DLBCL were included in this retrospective study. Demographic characteristics, disease-related findings, presence of central venous catheter and laboratory results of the patients were recorded. **Results:** The median age of the patients included in the study was 63.13±14.85 years. There were 67 female and 66 male patients, stage 1-2: 54 patients, stage 3-4: 79 patients at the time of diagnosis. Thrombosis was observed in 16 of the patients. Median ferritin levels were 357.42 ug/L and 253.07 ug/L, respectively, between the group with and without thrombosis (p:0.026). The ferritin value, which was examined for the presence of thrombosis, was determined as 227 ug/L as a result of the ROC analysis. In the logistic regression analysis, the risk of developing thrombosis was 6.1 times higher in those with a ferritin level ≥227 ug/L. **Conclusion:** Hyperferritinemia may be an independent risk factor for the development of thrombosis in DLBCL patients. In case of hyperferritinemia in patients, initiation of thromboprophylaxis may be an appropriate approach.

https://doi.org/10.1016/j.htct.2022.09.1244

PP 10

## RITUXIMAB INDUCED LUNG DISEASE IN A MANTLE CELL LYMPHOMA PATIENT RECEIVING MAINTENANCE: CASE PRESENTATION

Aslı Öztürkmen, Eyyüp Akkaya, Eren Davulcu, Emine Gültürk, Fehmi Hindilerden

*University of Health Sciences Hamidiye School of Medicine Bakırköy Dr. Sadi Konuk Training and Research Hospital*

**Introduction:** Rituximab-induced lung disease (R-ILD) is a rare entity that should be considered in patients treated with rituximab who present with dyspnea, fever, and cough but no clear evidence of infection. We describe the clinical presentation, management, and response to rechallenge in one mantle cell lymphoma patient who developed R-ILD during maintenance rituximab. Case report **Case:** 66 years old male with history of mantle cell lymphoma (MCL), who had been treated with RCHOP and underwent autologous stem cell transplantation (ASCT), was diagnosed with relapse 5 years after ASCT. Six courses of rituximab-bendamustine resulted in 2nd complete response and 2-monthly rituximab maintenance was initiated.10 days after 3rd rituximab , he presented with a 1 week history of progressive exertional dyspnea and cough. He was tachypneic and hypoxemic. **Methodology:** Thorax HRCT showed peripheral bilateral patchy ground glass opacities and nodular opacities. Bronchoalveolar lavage identified no bacterial,viral or fungal pathogen. With presumptive diagnosis of late R-ILD, methylprednisolone(MP) 1 mg/kg/day was started. In absence of rapidly progressing respiratory failure and fever, the patient was evaulated as non severe R-ILD. Thus, rechallenge with rituximab is being considered due to the risk of relapse of MCL. **Results:** Discussion: Reported rate of possible R-ILD is <0.03% in over 540,000 patients. Pulmonary complications of rituximab are hypersensitivity pneumonitis, ARDS, interstitial pneumonitis, organizing pneumonia, pulmonary fibrosis, and alveolar haemorrhage. Symptoms of R-ILD are dyspnea, fever, and hypoxemia and HRCT findings include focal alveolar densities, ground glass opacities and alveolar opacification. Time to symptom onset ranges from 1 day to several weeks after 1st infusion with mean **Conclusion:** mean duration of 3 months. Our patient had received rituximab prior to relapse and developed R-ILD after 9 doses of rituximab for relapse, which is a rare finding. All other causes of potential lung injury had to be meticulously excluded. ILD is a rare but potentially fatal pulmonary toxicity due to rituximab. As the symptoms at presentation are nonspecific, physicians must maintain a high index of suspicion to recognize it early and initiate treatment to avoid severe morbidity and mortality.

https://doi.org/10.1016/j.htct.2022.09.1245